Differentiating ischemic from hemorrhagic stroke using plasma biomarkers: The S100B/RAGE pathway

Montaner, Joan; Mendioroz, Maite; Delgado, Pilar; García‐Berrocoso, Teresa; Giralt, Dolors; Merino, Cristina; Ribó, Marc; Rosell, Anna; Peñalba, Anna; Fernández‐Cadenas, Israel; Romero, Francisco J.; Molina, Carlos A.; Álvarez-Sabín, José; Hernández-Guillamón, Mar

doi:10.1016/j.jprot.2012.01.033

Cited by 66 publications

(65 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A large study recently showed the ability of the S100B/RAGE BBM panel to distinguish between IS and ICH in a sample of 915 stroke patients (AUC 0.76) [35]. In blood sampled within 6 h from symptom onset, S100B was elevated, whereas sRAGE was lower in ICH patients compared to patients with IS.…”

Section: Selection Of Blood Biomarkers In Ichmentioning

confidence: 99%

Potential Role of Blood Biomarkers in the Management of Nontraumatic Intracerebral Hemorrhage

Senn

Elkind

Montaner³

et al. 2014

Cerebrovasc Dis

Self Cite

View full text Add to dashboard Cite

Background: Intracerebral hemorrhage (ICH), a subtype of stroke associated with high mortality and disability, accounts for 13% of all strokes. Basic and clinical research has contributed to our understanding of the complex pathophysiology of neuronal injury in ICH. Outcome rates, however, remain stable, and questions regarding acute management of ICH remain unanswered. Newer research is aiming at matching measured levels of serum proteins, enzymes, or cells to different stages of brain damage, suggesting that blood biomarkers may assist in acute diagnosis, therapeutic decisions, and prognostication. This paper provides an overview on the most promising blood biomarkers and their potential role in the diagnosis and management of spontaneous ICH. Summary: Information was collected from studies, reviews, and guidelines listed in PubMed up to November 2013 on blood biomarkers of nontraumatic ICH in humans.We describe the potential role and limitations of GFAP, S100B/RAGE, and ApoC-III as diagnostic biomarkers, F-Amyloid as a biomarker for etiological classification, and 27 biomarkers for prognosis of mortality and functional outcome. Within the group of prognostic markers we discuss markers involved in coagulation processes (e.g., D-Dimers), neuroendocrine markers (e.g., copeptin), systemic metabolic markers (e.g., blood glucose levels), markers of inflammation (e.g., IL-6), as well as growth factors (e.g., VEGF), and others (e.g., glutamate). Some of those blood biomarkers are agents of pathologic processes associated with hemorrhagic stroke but also other diseases, whereas others play more distinct pathophysiological roles and help in understanding the basic mechanisms of brain damage and/or recovery in ICH. Key Messages: Numerous blood biomarkers are associated with different pathophysiological pathways in ICH, and some of them promise to be useful in the management of ICH, eventually contributing additional information to current tools for diagnosis, therapy monitoring, risk stratification, or intervention. Up to date, however, no blood biomarker of ICH has been studied sufficiently to find its way into clinical routine yet; well-designed, large-scale, clinical studies addressing relevant clinical questions are needed. We suggest that the effectiveness of biomarker research in ICH might be improved by international cooperation and shared resources for large validation studies, such as provided by the consortium on stroke biomarker research (http://stroke-biomarkers.com/page.php?title=Resources). i 2014 S. Karger AG, Basel

show abstract

Section: Selection Of Blood Biomarkers In Ichmentioning

confidence: 99%

Potential Role of Blood Biomarkers in the Management of Nontraumatic Intracerebral Hemorrhage

Senn

Elkind

Montaner³

et al. 2014

Cerebrovasc Dis

Self Cite

View full text Add to dashboard Cite

show abstract

“…Previous studies, conducted in patients with stroke, showed that soluble RAGE increase in serum after ischemic and hemorrhagic stroke as respect to control population [7,21] and identified low levels of sRAGE in the blood of intracerebral hemorrhagic patients compared with those presenting ischemic stroke [22]. The differences of sRAGE levels among different stroke subtypes could be related to acute stroke severity rather than different etiologies of the stroke subtypes [23].…”

Section: Discussionmentioning

confidence: 90%

Soluble RAGE levels in plasma of patients with cerebrovascular events

Falcone¹,

Beigrezaei²,

Angela³

et al. 2017

Glob Drugs Therap

View full text Add to dashboard Cite

“…Other studies have also reached a similar conclusion. [26,27] This study has few limitations. We did not correlate the radiologic finding of CT Brain such as the size of the haemorrhage with CRP levels, as we intended to find the clinical outcome.…”

Section: Discussionmentioning

confidence: 95%